Dignify Therapeutics Highlights Clinical Development Plans at BIO CEO & Investor Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2025 /PRNewswire/ -- Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological conditions, presented its clinical development plans for its lead assets, DTI-117 and DTI-301, at the BIO CEO & Investor Conference held in New York on February 10-11, 2025.

During the conference, Dignify CEO Anthony DiTonno provided an update of the company's progress and strategic direction. He emphasized Dignify Therapeutics' commitment to developing innovative therapies for individuals affected by spinal cord injuries, diabetes, Parkinson's disease, and other neurological conditions.

DTI-301 and DTI-117 are at the forefront of the company's pipeline and are treatments for bladder and bowel dysfunction associated with neurological conditions and the aging process. Currently, many of these individuals require bladder catheterization for bladder emptying and an invasive, time-consuming manual bowel program for bowel evacuation.

Dignify's lead drug program, DTI-301, is a suppository that patients use as needed for bowel evacuation. DTI-301 induces defecation within 5-10 minutes, with minimal absorption and systemic exposure. Dignify's second drug program, DTI-117, is currently in development for on-demand emptying of both the bladder and bowel. DTI-117 directly stimulates smooth muscle contraction in the bladder and bowel, produces voiding in less than 10 minutes, and is rapidly eliminated from the body.

About Dignify Therapeutics
Dignify Therapeutics is a biotechnology company focused on developing therapies to restore voluntary bowel and bladder function in individuals with neurological conditions. The company's mission is to improve the quality of life for individuals affected by neurological disorders, and the elderly.
For more information about Dignify Therapeutics and its clinical development programs, please visit www.dignifytherapeutics.com.

About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference serves as a premier platform for biotech companies to engage with investors and industry leaders, fostering discussions on the latest advancements and investment opportunities in the biotechnology sector.

SOURCE Dignify Therapeutics